



AMRYT PHARMA PLC

Form of Proxy

General Meeting (the “Meeting”) of
Amryt Pharma plc (the “Company”)
to be held at the Company’s headquarters at 45 Mespil Road, Dublin 4, Ireland
at 2:00 p.m. GMT (9:00 a.m. EST) on March 2, 2022

The Directors have decided to hold the Meeting at the Company’s headquarters in Dublin, Ireland at 2:00 p.m. GMT (9:00 a.m. EST) on March 2, 2022. The health and welfare of our shareholders (“Shareholders”) and colleagues is our priority in making arrangements for the Meeting. Therefore, in planning the Meeting, we have been mindful above all of the need to ensure a COVID-secure meeting with appropriate social distancing for any Shareholders who might wish, subject to the UK and Irish Governments’ ongoing guidance on public gatherings relating to the COVID-19 pandemic, to attend the Meeting in person. The Company continues to closely monitor the evolving situation in respect of COVID-19.

The Meeting will take place at the time, date and venue stated above. Shareholders are strongly encouraged to vote in advance of the Meeting by lodging a completed Form of Proxy or submitting an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service, and appointing the Chairman of the Meeting as their proxy. This means that the Chairman of the Meeting will be able to vote on their behalf, and in accordance with their instructions, at the Meeting.

We will continue to monitor developments, including the latest UK and Irish Governments’ measures relating to COVID-19, and in the event that the Meeting arrangements change, the Company will issue an announcement via our website at <https://amrytpharma.com/newsroom/>. Any Shareholder or proxy attending the Meeting is required to provide proof of a negative result of a COVID-19 antigen test (taken no more than 48 hours prior to the Meeting) on arrival to the Meeting. If you are experiencing any of the symptoms connected with Covid-19 or are a close contact of someone with COVID-19, we would ask that you please do not attend the Meeting.

To support engagement with our Shareholders, the Company intends to provide a telephone facility to allow Shareholders to listen to the formal business of the Meeting. Any such Shareholder participation via the telephone facility will not constitute formal attendance at the Meeting, and Shareholders will not be able to vote on any resolutions via the telephone facility.

The dial-in numbers for Shareholders (or their duly appointed proxies or corporate representatives) to access the telephone facility are as follows: Ireland: +353 (0) 1 506 0626; UK: +44 (0) 203 009 5709 and US: +1 646 787 1226 (Passcode: 4345819). Please note that if you appoint any person other than the Chairman of the Meeting as your proxy, that person will need to attend the Meeting in person to cast your vote as directed. Such person will not be deemed to have attended the Meeting in person by dialling into the telephone facility.

The Company also encourages Shareholders to submit questions to, or raise matters of concern in relation to the formal business of the Meeting with, the Board by email to ir@amrytpharma.com, to arrive by no later than 2:00 p.m. GMT (9:00 a.m. EST) on February 25, 2022. Please include your full name and contact details. The Company will endeavour to answer any questions received by Shareholders by the time specified above during the Meeting. The Board will keep the situation under review and may need to make changes to the arrangements relating to the Meeting, including how it is conducted, and Shareholders should therefore continue to monitor the Company’s website for any update.

Unless otherwise defined herein, capitalised terms in this Form of Proxy shall have the meanings given to them in the notice of general meeting of the Company dated and published on February 2, 2022 (the “Notice”).

If you hold your shares in certificated form, you may appoint a proxy by completing this Form of Proxy or by submitting your proxy electronically at www.signalshares.com (please refer to note 11).

The Board strongly encourages Shareholders to appoint the Chairman of the Meeting as their proxy to cast their votes as directed.

AMRYT PHARMA PLC

Form of Proxy

I/We
 being a member/members of the Company, hereby appoint the Chairman of the Meeting or (see note 3)

Full name of proxy.....
 as my/our proxy to attend and vote on my/our behalf at the general meeting of the Company to be held at the Company's headquarters at 45 Mespil Road, Dublin 4, Ireland at 2:00 p.m. GMT (9:00 a.m. EST) on March 2, 2022 and at any adjournment thereof.

I/We instruct my/our appointed proxy to vote as indicated below in respect of the Resolutions which are referred to on page 7 of the Notice.

Please tick here if you are appointing more than one proxy (see note 5).

Number of Ordinary Shares proxy appointed over (see note 5).

Please mark "X" to indicate how you wish to vote.

| Ordinary Resolutions | For | Against | Vote Withheld |
|--|-----|---------|---------------|
| 1. To approve the form of share repurchase contracts and the counterparties. | | | |
| 2. To receive and adopt (a) the financial statements for the period from incorporation to July 31, 2020, together with the directors' and auditor's reports thereon (the " July 2020 Report "); and (b) the financial statements for the period from August 1, 2020 to December 31, 2020, together with the directors' and auditor's reports thereon (the " December 2020 Report "). | | | |
| 3. To approve the (a) the directors' remuneration report (excluding the directors' remuneration policy) as set out in the July 2020 Report; and (b) the directors' remuneration report (excluding the directors' remuneration policy) as set out in the December 2020 Report. | | | |
| 4. To approve the directors' remuneration policy as set out in the December 2020 Report. | | | |

Signature or execution: Date:

- 1. The Company continues to closely monitor the evolving situation in respect of COVID-19. The health and welfare of our Shareholders and colleagues is our priority in making arrangements for the Meeting. Therefore, in planning the Meeting, we have been mindful above all of the need to ensure a COVID-secure meeting with appropriate social distancing for any Shareholders who might wish, subject to UK and Irish Governments' ongoing guidance on public gatherings relating to the COVID-19 pandemic, to attend the Meeting in person. Shareholders are strongly encouraged to vote in advance of the Meeting by lodging a completed Form of Proxy or submitting an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service, and appointing the Chairman of the Meeting as their proxy to cast their votes as directed.** Any Shareholder or proxy attending the Meeting is required to provide proof of a negative result of a COVID-19 antigen test (taken no more than 48 hours prior to the Meeting) on arrival to the Meeting. If you are experiencing any of the symptoms connected with Covid-19 or are a close contact of someone with COVID-19, we would ask that you please do not attend the Meeting.
2. To support engagement with Shareholders, the Company intends to provide a telephone facility to allow Shareholders to listen to the formal business of the Meeting. Any such Shareholder participation via the telephone facility will not constitute formal attendance at the Meeting, and Shareholders will not be able to vote on any resolutions via the telephone facility. The dial-in numbers for Shareholders (or their duly appointed proxies or corporate representatives) to access the telephone facility are as follows: Ireland: +353 (0) 1 506 0626; UK: +44 (0) 203 009 5709 and US: +1 646 787 1226 (Passcode: 4345819). Please note that if you appoint any person other than the Chairman of the Meeting as your proxy, that person will need to attend the Meeting in person to cast your vote as directed. Such person will not be deemed to have attended the Meeting in person by dialling into the telephone facility. The Company also encourages Shareholders to submit questions to, or raise matters of concern in relation to the formal business of the Meeting with, the Board by email to ir@amrytpharma.com, to arrive by no later than 2:00 p.m. GMT (9:00 a.m. EST) on February 25, 2022. Please include your full name and contact details. The Company will endeavour to answer any questions received by Shareholders by the time specified above during the Meeting. The Board will keep the situation under review and may need to make changes to the arrangements relating to the Meeting, including how it is conducted, and Shareholders should therefore continue to monitor the Company's website for any update.
3. To be entitled to attend and vote at the Meeting (or any adjournment thereof) (and for the purpose of the determination by the Company of the number of votes that can be cast thereat), Shareholders must be registered in the register of members of the Company as at 6:00 p.m. on February 28, 2022 (or, in the case of any adjournment of the Meeting, no later than 48 hours (excluding any part of a day that is not a Business Day) before the time appointed for the holding of the adjourned general meeting). Changes to the register of members of the Company after the relevant deadline shall be disregarded in determining the rights of any person to attend and vote at the Meeting (or any adjournment thereof). **However, as set out in note 1, the Board strongly encourages Shareholders to vote on all resolutions being proposed at the Meeting by lodging a completed Form of Proxy or submitting an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service, and appointing the Chairman of the Meeting as their proxy to cast their votes as directed.**
4. A Shareholder who is entitled to attend and vote at the Meeting (or any adjournment thereof) is entitled to appoint another person or persons as its proxy or proxies to exercise all or any of the Shareholder's rights to attend and vote at the Meeting (or any adjournment thereof). If a Shareholder wishes to appoint more than one proxy, each proxy must be appointed to exercise the rights attached to a different Ordinary Share or Ordinary Shares held by the Shareholder. A proxy need not be a member of the Company but must attend the Meeting (and any adjournment thereof). You can (and are strongly encouraged by the Board to) appoint the Chairman of the Meeting as your proxy. If you wish to appoint someone other than the Chairman of the Meeting, insert the full name of your appointee in the appropriate box. If you sign and return this Form of Proxy with no name inserted in the box, the Chairman of the Meeting will be deemed to be your proxy.
5. If you wish to appoint more than one proxy, you may: (a) photocopy this Form of Proxy, fill in the name of the proxy and the number of Ordinary Shares in respect of which the proxy is appointed and send the multiple forms together to Link Group at the address in note 10; or alternatively (b) call or email Link Group on the number in note 16 who will then issue you with multiple Forms of Proxy. Please also indicate by ticking the box provided if the proxy instruction is one of multiple instructions being given. Please ensure that for each proxy appointed in this way, you fill in, in the box provided, the number of Ordinary Shares in respect of which each proxy is appointed. If you are appointing a proxy in relation to less than your full voting entitlement, please enter in the box provided the number of Ordinary Shares in relation to which they are authorised to act as your proxy. If left blank your proxy will be deemed to be authorised in respect of your full voting entitlement (or if the Form of Proxy has been issued in respect of a designated account for a Shareholder, the full voting entitlement for that designated account). All Forms of Proxy must be signed and should be returned together in a single envelope, rather than posted separately, if possible.
6. To direct your proxy how to vote on the resolutions being proposed at the Meeting mark the appropriate box with an 'X'. If no voting indication is given, your proxy will vote, or abstain from voting, at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the Meeting. The 'vote withheld' option is to enable you to abstain on any of the resolutions. However, it should be noted that a vote withheld is not a vote in law and will not be counted in the proportion of votes 'for' and 'against' the relevant resolution.
7. In the case of joint Shareholders, only one need sign the Form of Proxy. The vote of the senior joint Shareholder will be accepted to the exclusion of the votes of the other joint Shareholders. For this purpose, seniority will be determined by the order in which the names of the Shareholders appear in the register of members of the Company in respect of the joint shareholding.
8. A corporation should execute the Form of Proxy under its common seal or otherwise in accordance with section 44 of the Companies Act or by signature on its behalf by a duly authorised officer or attorney whose power of attorney or other authority should be enclosed with the Form of Proxy.
9. Any power of attorney or any other authority under which the Form of Proxy is signed (or a duly certified, or notarially authenticated copy if executed outside the UK, copy of such power or authority) must be included with the Form of Proxy.

10. On completing the Form of Proxy, sign and return it (together with any other Form of Proxy completed and signed by you (please refer to note 5)) to Link Group using the pre-paid envelope provided for use in the UK. If sending from outside the UK, the correct postage will need to be applied. You may, if you prefer, return this Form of Proxy in a sealed stamped envelope to the address referred to below in this note 10. To be valid, the Form of Proxy, together with any power of attorney or other authority under which the Form of Proxy is signed (or a duly certified, or notarially authenticated copy if executed outside the UK, copy of such power or authority) must be received at the offices of PXS 1, Link Group, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom by no later than 2:00 p.m. GMT (9:00 a.m. EST) on February 28, 2022 (or, in the case of any adjournment of the Meeting, no later than 48 hours (excluding any part of a day that is not a Business Day) before the time appointed for the holding of the adjourned general meeting). Please return this Form of Proxy by hand or by post (during normal business hours) to PXS 1, Link Group, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom.
11. Alternatively, you can submit your proxy vote via the internet through the share portal service at www.signalshares.com. To do so, you will need to log on to your share portal account or register for the share portal if you have not already done so. To register for the share portal you will need your investor code. Once registered, you will immediately be able to vote. For an electronic proxy appointment to be valid, the appointment must be received no later than 2:00 p.m. GMT (9:00 a.m. EST) on February 28, 2022 (or, in the case of any adjournment of the Meeting, no later than 48 hours (excluding any part of a day that is not a Business Day) before the time appointed for the holding of the adjourned general meeting). If you want to appoint more than one proxy electronically then please contact the Company's registrar using the contact details at note 16.
12. Shareholders who hold through CREST and who wish to appoint a proxy through the CREST proxy voting service for the Meeting (or any adjournment thereof) may do so by using the procedures described in the CREST Manual (available at www.euroclear.com). If you hold your Ordinary Shares in CREST and you wish to appoint a proxy or proxies through the CREST electronic proxy appointment service, details of how to do so are set out on pages 9 to 10 of the Notice.
13. The return of a completed Form of Proxy or the submission of an electronic filing via the share portal service or a proxy instruction via the CREST proxy voting service (as described above) will not prevent a Shareholder from attending the Meeting (or any adjournment thereof) and voting in person if he/she wishes to do so.
14. A Shareholder may change a proxy instruction but to do so you will need to contact the Company's registrar, Link Group. The revocation notice must be received by Link Group by no later than 2:00 p.m. GMT (9:00 a.m. EST) on February 28, 2022 (or, in the case of any adjournment of the Meeting, no later than 48 hours (excluding any part of a day that is not a Business Day) before the time appointed for the holding of the adjourned general meeting). If you attempt to revoke your proxy appointment but the revocation is received after the time specified, your original proxy appointment will remain valid unless you attend the Meeting (or any adjournment thereof) and vote in person.
15. If two or more valid but different instruments of proxy are delivered in respect of the same Ordinary Share for use at the Meeting (or any adjournment thereof) the one which is last validly deposited or received shall be treated as replacing and revoking the other Form of Proxy as regards that Ordinary Share. Which proxy is later will be determined on the basis of which proxy is last sent (or, if the Company is unable to determine which is last sent, last received). Proxies in the same envelope will be treated as sent and received at the same time, to minimise the number of conflicting proxies. If conflicting proxies are sent or received at the same time or if the Company is unable to determine which was sent or received last in respect of (or deemed to be in respect of) an entire holding, none of them shall be treated as valid.
16. If you have any questions relating to the completion and/or return of this Form of Proxy, please contact the Company's registrar, Link Group, on +44 (0)371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline is open between 9.00 a.m. and 5.30 p.m. (BST), Monday to Friday excluding public holidays in England and Wales. Different charges may apply to calls from mobile telephones and calls may be recorded and randomly monitored for security and training purposes. Alternatively, you may submit a request in writing to Link Group by post to PXS 1, Link Group, Central Square, 29 Wellington Street, Leeds, LS1 4DL, United Kingdom or by email to shareholderenquiries@linkgroup.co.uk. Please note that Link Group cannot provide advice on the merits of the proposals referred to in the Notice or give any financial, legal or tax advice.
17. Shareholders satisfying the thresholds in section 527 of the Companies Act can require the Company to publish a statement on its website setting out any matter relating to (a) the audit of the Company's accounts (including the auditor's report and the conduct of the audit) that are to be laid before the Meeting; or (b) any circumstances connected with an auditor of the Company ceasing to hold office since the last annual general meeting, that the Shareholders propose to raise at the Meeting. The Company cannot require the Shareholders requesting the publication to pay its expenses. Any statement placed on the website must also be sent to the Company's auditors no later than the time it makes its statement available on the website. The business which may be dealt with at the Meeting includes any such statement that the Company has been required to publish on its website.
18. You may not use any electronic address (within the meaning of section 333(4) of the Companies Act) provided in this Form of Proxy or any related documents (including the Notice) to communicate with the Company for any purposes other than those expressly stated.
19. Unless otherwise defined herein, capitalised terms in this Form of Proxy shall have the meanings given to them in the Notice.
20. The Company may process personal data of attendees and participants at the Meeting. This may include webcasts, photos, recording and audio and video links, as well as other forms of personal data. The Company shall process such personal data in accordance with its privacy policy, which can be found at www.amrytpharma.com
21. Please note that the Company takes all reasonable precautions to ensure no viruses are present in any electronic communication it sends out but the Company cannot accept responsibility for loss or damage arising from the opening or use of any email or attachments from the Company and recommends that Shareholders subject all messages to virus checking procedures prior to use. Any electronic communication received by the Company, including any electronic filing, that is found to contain any virus will not be accepted.